Evaluating the Real-World Value of Daratumumab Addition to Multiple Myeloma Induction Therapy by Real-World Minimal Residual Disease Assessment and Extended Genetic Profiling.

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial.

Impact of Ultra High-risk Genetics on Real-world Outcomes of Transplant-eligible Multiple Myeloma Patients.

An analysis of the false negative rate of minimal residual disease measurement by multiparameter flow cytometry in multiple myeloma.

Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report.

The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience.

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.

Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?

Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.

Challenges and opportunities in healthcare volunteer management: insights from volunteer administrators.